A newly published study in ESMO Open (Jan 2025) led by H. S. Rugo, R. M. Layman, F. Lynce, G. Curigliano, A. Brufsky, and colleagues analyzed real-world overall survival (OS) outcomes for palbociclib, ribociclib, and abemaciclib as first-line (1L) treatment for HR+/HER2- metastatic breast cancer (MBC).
Using real-world data from Flatiron Health’s electronic records, the study evaluated 9,146 patients treated between 2015 and 2023. After adjusting for baseline characteristics, the results showed no significant OS differences between the three CDK4/6 inhibitors when combined with an aromatase inhibitor.
These findings reinforce that treatment selection should consider safety, tolerability, and quality of life, rather than overall survival differences. The study provides valuable insights for clinicians optimizing CDK4/6i therapy in real-world practice.
Read the full study: https://lnkd.in/etwibTAm
What are your thoughts on these real-world findings? Let’s discuss.
